These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 9700724)

  • 61. Isotype-specific human suppressor T cells for IgE synthesis activated by IgE-anti-IgE immune complexes.
    Hassner A; Saxon A
    J Immunol; 1984 Jun; 132(6):2844-9. PubMed ID: 6233363
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Antitumor xenograft activity with a conjugate of a Vinca derivative and the squamous carcinoma-reactive monoclonal antibody PF1/D.
    Johnson DA; Laguzza BC
    Cancer Res; 1987 Jun; 47(12):3118-22. PubMed ID: 3495327
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Clearance of IgE from serum of normal and hybridoma-bearing mice.
    Haba S; Ovary Z; Nisonoff A
    J Immunol; 1985 May; 134(5):3291-7. PubMed ID: 3980994
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Melittin-specific monoclonal and polyclonal IgE and IgG1 antibodies from mice.
    King TP; Kochoumian L; Joslyn A
    J Immunol; 1984 Nov; 133(5):2668-73. PubMed ID: 6207240
    [TBL] [Abstract][Full Text] [Related]  

  • 65. [Monoclonal antitumor antibodies--its application to diagnosis and treatment of tumors].
    Taniguchi M; Wakabayashi S
    Gan No Rinsho; 1983 May; 29(6):654-8. PubMed ID: 6876435
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Characterization and isolation of IgE class-specific suppressor factor (IgE-TsF) I. The presence of the binding site(s) for IgE and of the H-2 gene products in IgE-TsF.
    Suemura M; Shiho O; Deguchi H; Yamamura Y; Böttcher I; Kishimoto T
    J Immunol; 1981 Aug; 127(2):465-71. PubMed ID: 6788842
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Opsonic, cytotoxic, precipitating, blocking of bacterial adherence, and other activities of monoclonal IgE antibody compared with IgA and IgM.
    Tlaskalová-Hogenová H; Simecková J; Vĕtvicka V; Fornůsek L; TalaFantová M; Mancal P
    Immunology; 1984 Nov; 53(3):427-33. PubMed ID: 6436172
    [TBL] [Abstract][Full Text] [Related]  

  • 68. IgE class-restricted tolerance induced by neonatal administration of soluble or cell-bound IgE. Cellular mechanisms.
    Chen SS; Liu FT; Katz DH
    J Exp Med; 1984 Oct; 160(4):953-70. PubMed ID: 6237166
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Comparison of IgE and IgG antibody-dependent cytotoxicity in vitro and in a SCID mouse xenograft model of ovarian carcinoma.
    Gould HJ; Mackay GA; Karagiannis SN; O'Toole CM; Marsh PJ; Daniel BE; Coney LR; Zurawski VR; Joseph M; Capron M; Gilbert M; Murphy GF; Korngold R
    Eur J Immunol; 1999 Nov; 29(11):3527-37. PubMed ID: 10556807
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Specific inhibition of IgE antibody production by an antisense oligodeoxynucleotide oligomer (Oligostick).
    Hall TJ; Brostoff J
    Immunology; 1992 Nov; 77(3):462-4. PubMed ID: 1478691
    [TBL] [Abstract][Full Text] [Related]  

  • 71. c7E3 Fab inhibits human tumor angiogenesis in a SCID mouse human skin xenograft model.
    Nakada MT; Cao G; Sassoli PM; DeLisser HM
    Angiogenesis; 2006; 9(4):171-6. PubMed ID: 17109195
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Macrophage receptors for IgE: binding of IgE to specific IgE Fc receptors on a human macrophage cell line, U937.
    Anderson CL; Spiegelberg HL
    J Immunol; 1981 Jun; 126(6):2470-3. PubMed ID: 7014719
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Using the allergic immune system to target cancer: activity of IgE antibodies specific for human CD20 and MUC1.
    Teo PZ; Utz PJ; Mollick JA
    Cancer Immunol Immunother; 2012 Dec; 61(12):2295-309. PubMed ID: 22692757
    [TBL] [Abstract][Full Text] [Related]  

  • 74. In vivo suppression of Ehrlich ascites carcinoma by human antibody-dependent splenocytes.
    Dobaczewska H
    Neoplasma; 1984; 31(2):165-8. PubMed ID: 6717686
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Therapy of a murine sarcoma using syngeneic monoclonal antibody.
    Kennel SJ; Lankford T; Flynn KM
    Cancer Res; 1983 Jun; 43(6):2843-8. PubMed ID: 6850596
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Glucuronidation associated with intrinsic resistance to mycophenolic acid in human colorectal carcinoma cells.
    Franklin TJ; Jacobs V; Jones G; Plé P; Bruneau P
    Cancer Res; 1996 Mar; 56(5):984-7. PubMed ID: 8640790
    [TBL] [Abstract][Full Text] [Related]  

  • 77. High prevalence of human anti-mouse antibodies in the serum of colorectal cancer patients.
    Goto M; Kuribayashi K; Umemori Y; Ohe Y; Asanuma K; Tanaka M; Kobayashi D; Watanabe N
    Anticancer Res; 2010 Oct; 30(10):4353-6. PubMed ID: 21036763
    [TBL] [Abstract][Full Text] [Related]  

  • 78. [Can monoclonal antibodies to a carcinoma-specific cell surface molecule prevent liver metastasis of human colorectal carcinoma and effectively treat already existing micrometastases?].
    Burkart C; Porschen R
    Z Gastroenterol; 1996 Jan; 34(1):41-2. PubMed ID: 8776175
    [No Abstract]   [Full Text] [Related]  

  • 79. Antibody-mediated suppression of tumor growth. III. Molecular assay of murine IgG1 alloantibody required to cause tumor suppression in vivo.
    Johnson RJ; Pasternack GR; Drysdale BE; Shin HS
    J Immunol; 1977 Feb; 118(2):498-504. PubMed ID: 839068
    [TBL] [Abstract][Full Text] [Related]  

  • 80. [Application of monoclonal antibody for cancer therapy].
    Yamaguchi T; Takahashi T
    Gan To Kagaku Ryoho; 1994 Feb; 21(2):157-62. PubMed ID: 8311485
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.